600267:SSEZhejiang Hisun Pharmaceutical Co., Ltd. Class A Analysis

Zhejiang Hisun Pharmaceutical is trading at CNY 9.48, notably below its 20‑day (CNY 10.42), 50‑day (CNY 10.76) and 200‑day (CNY 10.63) simple moving averages, signaling a short‑term price weakness. The RSI of 24.7 places the stock in oversold territory, while a bearish MACD (negative histogram) and decreasing volume suggest limited buying pressure at current levels. Yet the price sits just above the calculated support of CNY 9.39 and far below the DCF‑derived fair value of CNY 25.48, indicating a substantial valuation gap. The P/E of 15.8 is well under the industry average of 27.8, reinforcing the cheapness of the stock.
Fundamentally, the company posted a 9.2% revenue decline and modest profit margin of 6.8%, but it maintains healthy gross (45.8%) and operating (15.5%) margins. Strong cash generation (operating cash flow CNY 2.22 bn, free cash flow CNY 2.37 bn) and a low debt‑to‑equity of 24.2% underpin a sustainable dividend yield of 1.88% with a 35% payout. Low beta (0.45) and moderate 30‑day volatility (23.8%) suggest limited price swings, while the “Extreme Greed” market sentiment adds a bullish backdrop. Overall, the stock appears significantly undervalued with a solid balance sheet, making it attractive for value‑oriented investors.